13Aug/19
Personalized cancer vaccine! Melanoma treatment vaccine TLPLDC reduces the risk of recurrence by 50%
Recently, Elios Therapeutics released positive top-line data to evaluate the clinical trial of TLPLDC (tumor lysate, particle loading, dendritic cell) vaccine in the treatment of melanoma in phase IIb. 1.Research result ThisRead More…